Series A-C fund research profile
Eight Roads is the Fidelity-backed global venture platform’s India franchise, with a concentrated technology, consumer, financial-services and healthcare portfolio. Its clearest dedicated vehicle is the $250M healthcare and lifesciences fund, while the wider platform backs enterprise and consumer scale-ups as well.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Eight Roads Ventures (India) uses a series a-c approach across Health, fintech, SaaS.
Current evidence
Eight Roads' India platform reports $1.6B of allocated capital and 80+ portfolio companies; its 2026 India updates include Shadowfax and named portfolio activity across healthcare, technology and consumer sectors.
Strategy
Series A-C
Sector focus
Health, fintech, SaaS
AIF structure context
Indian venture capital and angel-fund strategies are commonly structured as Category I AIFs. Verify the specific vehicle and registration before investing.
Current signal
Eight Roads' India platform reports $1.6B of allocated capital and 80+ portfolio companies; its 2026 India updates include Shadowfax and named portfolio activity across healthcare, technology and consumer sectors.
Investor questions
Eight Roads Ventures (India) is covered in Rupeia's venture capital research universe. The current public record describes the strategy as Series A-C, with a sector focus of Health, fintech, SaaS. The profile should be read with the linked source trail and Typical route: Category I AIF context.
The profile displays only company or asset names attributable to Eight Roads Ventures (India) in the reviewed public sources: Wint Wealth Series B co-investor (Jan 2026, press-verified), Chaayos, Pharmeasy (early). It does not represent a complete current portfolio unless the manager has published one.
The GP says the India franchise has backed more than 60 companies since 2007 and manages $1.6B in India. Public reporting identifies outcomes including the Cygnus/Ujala transaction and the API Holdings/PharmEasy public-market story; no India fund-level return is disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Eight Roads announced a dedicated $250M India healthcare and lifesciences fund in 2022 and said total India capital managed reached $1.6B. The global network separately states more than $8B managed across regions.. Public terms or access information: The healthcare vehicle is sub-segment, stage and investment-size agnostic, targeting 15–20 companies over three to four years with investments ranging from smaller cheques up to $40M. The wider India strategy spans early to growth-stage technology, consumer and fintech.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Prem Pavoor, Shweta Bhatia. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review stage concentration, follow-on reserves, company failure rates, dilution, exit timing and the gap between paper valuations and realised distributions. The current open diligence point is: Current India vintage size.
2026-02: Eight Roads' India platform reports $1.6B of allocated capital and 80+ portfolio companies; its 2026 India updates include Shadowfax and named portfolio activity across healthcare, technology and consumer sectors.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.